Legal & General Group
ZBIO

Legal & General Group’s Zenas BioPharma ZBIO Stock Holding History

Legal & General Group’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$204K Sell
10,432
-2,595
-20% -$58.2K ﹤0.01% 2536
2025
Q4 		$473K Buy
13,027
+11,673
+862% +$384K ﹤0.01% 2449
2025
Q3 		$30K Sell
1,354
-194
-13% -$3.16K ﹤0.01% 2890
2025
Q2 		$15K Buy
1,548
+29
+2% +$282 ﹤0.01% 3131
2025
Q1 		$12K Hold
1,519
– – ﹤0.01% 3116
2024
Q4 		$12.4K Buy
+1,519
New +$23.7K ﹤0.01% 3200

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return

Legal & General Group's ZBIO Position: Q1 2026 in Review

Legal & General Group reduced its Zenas BioPharma (ZBIO) stake by 20% in Q1 2026, selling an estimated $58.2K and leaving 10,432 shares worth $204K. The position accounts for ﹤0.01% of the portfolio, ranked #2536.

Legal & General Group first reported a position in ZBIO in Q4 2024 and has held it in 6 quarters since. The position peaked at $473K in Q4 2025. 139 funds tracked by Wall St. Rank hold ZBIO as of Q1 2026.

  • Legal & General Group held 10,432 shares of Zenas BioPharma worth $204K as of Q1 2026.
  • Legal & General Group sold 2,595 Zenas BioPharma shares in Q1 2026, an estimated $58.2K.
  • Zenas BioPharma made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #2536 holding.
  • Legal & General Group first reported a position in Zenas BioPharma in Q4 2024 and has held it in 6 quarters since.
  • Legal & General Group's Zenas BioPharma position peaked at $473K in Q4 2025.
  • 139 funds tracked by Wall St. Rank held Zenas BioPharma as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.